MODAG GmbH clinical trials
The registry lists 6 studies whose lead sponsor is MODAG GmbH. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 31, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 6studies on the registry
- 3open to participants now
- 3reach primary completion within a year
Get an email when these change. Save the MODAG GmbH studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs MODAG GmbH’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
3 of MODAG GmbH’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- 2MMay
- JJun
- 1JJul
- AAug
- SSep
- OOct
- NNov
All 3
- May 2027Evaluation of [¹⁸F]MODAG-009 PET Imaging in SynucleinopathiesNCT07640555
- May 2027Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy VolunteersNCT07617688
- Jul 2027Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot PhaseNCT07640542
Add all 3 to your calendar (.ics) → With an account.
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to MODAG GmbH.
- MODAG GmbH6 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 6 of 6.
- Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot PhaseRecruitingNCT07640542Early Phase 1
- Evaluation of [¹⁸F]MODAG-009 PET Imaging in SynucleinopathiesRecruitingNCT07640555Early Phase 1
- Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy VolunteersRecruitingNCT07617688Early Phase 1
- A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)CompletedNCT05532358Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's DiseaseCompletedNCT04685265Phase 1
- A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy SubjectsCompletedNCT04208152Phase 1